StockData
NEONasdaqServices-Testing LaboratoriesFiscal year ends December 31

NEOGENOMICS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$16.42−0.23 (-1.38%)

Close on Oct 19, 2026

Market cap
$2.15B
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Oct 27, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Jul 28, 2026After market close$202.00M$0.02$0.05
Q1 FY2026
Ended Mar 31, 2026
Apr 28, 2026After market close$187.00M$-0.13$0.01
Q4 FY2025
Ended Dec 31, 2025
Feb 17, 2026Before market open$190.00M$-0.08$0.06
Q3 FY2025
Ended Sep 30, 2025
Oct 28, 2025Before market open$188.00M$-0.21$0.03
Q2 FY2025
Ended Jun 30, 2025
Jul 29, 2025Before market open$181.00M––
Q1 FY2025
Ended Mar 31, 2025
Apr 29, 2025Before market open$168.00M$-0.20$0.00
Q4 FY2024
Ended Dec 31, 2024
Feb 18, 2025Before market open$172.00M$-0.12$0.04
Q3 FY2024
Ended Sep 30, 2024
Nov 5, 2024Before market open$168.00M$-0.14$0.05
Q2 FY2024
Ended Jun 30, 2024
Jul 29, 2024After market close$165.00M$-0.15$0.03
Q1 FY2024
Ended Mar 31, 2024
Apr 30, 2024Before market open–––
Q4 FY2023
Ended Dec 31, 2023
Feb 20, 2024After market close–––

Company guidance

Outlook given with results on Jul 28, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
Adjusted EBITDAnon-GAAPfull-year 2026$56.00M to $58.00MRaised
Adjusted diluted EPS (non-GAAP)non-GAAPYear Ended December 31, 2026$0.17 to $0.20Narrowed
Net loss per diluted share (GAAP)GAAPYear Ended December 31, 2026$-0.32 to $-0.26Raised
Net lossGAAPfull-year 2026-$42.00M to -$34.00MRaised
Consolidated revenuefull-year 2026$802.00M to $806.00MRaised

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Neogenomics filed with the SEC